Previous 10 | Next 10 |
MOORE KUEHN ANNOUNCES ENCOURAGES NOVOCURE LIMITED INVESTORS TO CONTACT LAW FIRM PR Newswire NEW YORK , July 14, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: ...
2023-07-06 13:17:16 ET Novocure (NASDAQ: NVCR) shares dropped after publishing the results of an important clinical trial. The headlines looked positive at first glance, but the study raised concerns that lung cancer treatment might not have a place in the market. As a result, the s...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2023 on Thursday, July 27, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...
2023-06-13 23:49:18 ET Summary NovoCure's Tumor Treating Fields (TTFields) technology is seeking FDA approval for use in non-small cell lung cancer (NSCLC), despite the company's recent stock decline. The Q1 2023 financial report shows decreased net revenues and increased expenses...
2023-06-12 05:39:00 ET These days, investors can find plenty of reasons to feel nervous about buying stocks. Surging inflation, soaring interest rates, and geopolitical tensions are all legitimate concerns for most businesses. In these challenging times, investors would do well to remem...
2023-06-07 08:38:13 ET NovoCure Limited ( NASDAQ: NVCR ) eked out a ~3% gain in the pre-market Wednesday as Wedbush upgraded the medical device maker to Neutral from Underperform, citing a favorable risk-reward setup following a ~43% slump in the previous session. Reviewing ...
2023-06-07 06:21:00 ET Stock index futures were slightly lower, with investors still reluctant to commit to a firm direction a week before CPI and the Fed. S&P futures ( SPX ) -0.1% , Dow futures ( INDU ) -0.2% and Nasdaq 100 futures ( NDX:IND ) -0.1% wer...
2023-06-06 21:51:06 ET Shares of NovoCure Limited ( NASDAQ: NVCR ) reached a 52-week low on Tuesday after the medical device maker and its China-based partner Zai Lab ( ZLAB ) posted late-stage data for their cancer treatment device, Tumor Treating Fields (TTFields), in patients...
2023-06-06 17:49:38 ET Summary NovoCure Limited's primary endpoint of phase 3 LUNAR study, using TTFields plus standard therapies for 2nd line metastatic NSCLC patients, was met with statistical significance with p-value of p=0.035. There is a Premarket Approval submission of TTFi...
2023-06-06 14:48:00 ET Wall Street has been on the upswing lately, gaining confidence about the ability of the economy to withstand inflationary pressures and tighter monetary policy. Small-cap stocks soared on Tuesday at midday, which helped drive the Nasdaq Composite (NASDAQINDEX: ^...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...